Management of Dental Abscesses in Patients with MRSA History

Primary Intervention and Antibiotic Recommendations

The Infectious Diseases Society of America recommends prioritizing incision and drainage as the primary intervention for dental abscesses in patients with MRSA history, and using clindamycin 300-450 mg orally three times daily as first-line therapy if antibiotics are indicated, provided local MRSA resistance rates to clindamycin are <10% 1, 2
The American Dental Association and the Infectious Diseases Society of America suggest that antibiotics should be added to drainage for dental abscesses when severe or extensive disease, signs of systemic illness, facial location, associated comorbidities, extremes of age, or lack of response to drainage alone are present 2

The Infectious Diseases Society of America recommends clindamycin as the preferred first-line oral antibiotic option, with adult dosing at 300-450 mg orally three times daily and pediatric dosing at 10-13 mg/kg/dose every 6-8 hours (maximum 40 mg/kg/day) 1, 2
The Centers for Disease Control and Prevention suggest that trimethoprim-sulfamethoxazole (TMP-SMX) can be used as an alternative option, with adult dosing at 1-2 double-strength tablets orally twice daily and pediatric dosing at trimethoprim 4-6 mg/kg/dose every 12 hours, but it has poor activity against beta-hemolytic streptococci 1, 2
The Infectious Diseases Society of America recommends doxycycline or minocycline as alternative options, with dosing at 100 mg orally twice daily (adults) for doxycycline and 200 mg loading dose, then 100 mg twice daily (adults) for minocycline, but they are not recommended for children <8 years or pregnant women 1, 2

The Infectious Diseases Society of America recommends a treatment duration of 5-10 days for uncomplicated dental abscess with adequate drainage and 7-14 days for complicated infection with systemic symptoms 2, 3
The American College of Emergency Physicians suggests that patients should be admitted for IV antibiotics if they have systemic toxicity present despite oral antibiotics, rapidly progressive infection, inability to achieve adequate surgical drainage, or airway compromise risk 1, 2

The Infectious Diseases Society of America advises against using beta-lactams alone (penicillin, amoxicillin, cephalexin) in patients with MRSA history, as they provide no MRSA coverage 3
The Centers for Disease Control and Prevention recommend against using rifampin as monotherapy or adding it routinely to other agents for skin/soft tissue infections, as resistance develops rapidly without proven benefit 1, 2
The American Dental Association emphasizes the importance of verifying local antibiogram before using clindamycin, as resistance patterns vary significantly by region 1, 2